Inflammatory breast cancer: Integration of irradiation, surgery, and chemotherapy

T. M. Pisansky, Daniel J Schaid, Charles Lawrence Loprinzi, J. H. Donohue, M. F. Schray, P. J. Schomberg

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Between January 1983 and April 1987, 36 consecutive patients with nonmetastatic clinical (30 patients) or occult (6 patients) inflammatory breast cancer were treated with irradiation, mastectomy, and chemotherapy. In 29 patients, treatment consisted of preoperative once daily (16 patients) or twice daily (13 patients) irradiation with concurrent chemotherapy. In 27 (93%) of these 29 patients, this treatment was followed by mastectomy and additional chemotherapy. In 25 (86%) of these patients, major clinical response was attained, but an examination of the pathology of the operative specimen revealed complete tumor absence in only two patients (7%). The remaining seven patients underwent immediate mastectomy followed by once daily irradiation and chemotherapy. With a median follow-up of 30.4 months in all patients (59.2 months in surviving patients), the 5-year probability of relapse-free survival was 24% and of overall survival, 34%. Overall, the probability at 5 years of initial isolated local-regional tumor recurrence was 19%; in patients treated with once daily irradiation, the 5-year probability was 28%, whereas the probability was 8% with twice daily (accelerated) fractionated irradiation. Chemotherapy dose intensity did not appear to be adversely affected by the use of irradiation. The treatment approach described herein provides results comparable with those in other contemporary American series.

Original languageEnglish (US)
Pages (from-to)376-387
Number of pages12
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number5
StatePublished - 1992

Fingerprint

Inflammatory Breast Neoplasms
Drug Therapy
Mastectomy
Recurrence
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inflammatory breast cancer : Integration of irradiation, surgery, and chemotherapy. / Pisansky, T. M.; Schaid, Daniel J; Loprinzi, Charles Lawrence; Donohue, J. H.; Schray, M. F.; Schomberg, P. J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 5, 1992, p. 376-387.

Research output: Contribution to journalArticle

@article{6109c13c8e3f4ed38c8b55e56efd511c,
title = "Inflammatory breast cancer: Integration of irradiation, surgery, and chemotherapy",
abstract = "Between January 1983 and April 1987, 36 consecutive patients with nonmetastatic clinical (30 patients) or occult (6 patients) inflammatory breast cancer were treated with irradiation, mastectomy, and chemotherapy. In 29 patients, treatment consisted of preoperative once daily (16 patients) or twice daily (13 patients) irradiation with concurrent chemotherapy. In 27 (93{\%}) of these 29 patients, this treatment was followed by mastectomy and additional chemotherapy. In 25 (86{\%}) of these patients, major clinical response was attained, but an examination of the pathology of the operative specimen revealed complete tumor absence in only two patients (7{\%}). The remaining seven patients underwent immediate mastectomy followed by once daily irradiation and chemotherapy. With a median follow-up of 30.4 months in all patients (59.2 months in surviving patients), the 5-year probability of relapse-free survival was 24{\%} and of overall survival, 34{\%}. Overall, the probability at 5 years of initial isolated local-regional tumor recurrence was 19{\%}; in patients treated with once daily irradiation, the 5-year probability was 28{\%}, whereas the probability was 8{\%} with twice daily (accelerated) fractionated irradiation. Chemotherapy dose intensity did not appear to be adversely affected by the use of irradiation. The treatment approach described herein provides results comparable with those in other contemporary American series.",
author = "Pisansky, {T. M.} and Schaid, {Daniel J} and Loprinzi, {Charles Lawrence} and Donohue, {J. H.} and Schray, {M. F.} and Schomberg, {P. J.}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "376--387",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Inflammatory breast cancer

T2 - Integration of irradiation, surgery, and chemotherapy

AU - Pisansky, T. M.

AU - Schaid, Daniel J

AU - Loprinzi, Charles Lawrence

AU - Donohue, J. H.

AU - Schray, M. F.

AU - Schomberg, P. J.

PY - 1992

Y1 - 1992

N2 - Between January 1983 and April 1987, 36 consecutive patients with nonmetastatic clinical (30 patients) or occult (6 patients) inflammatory breast cancer were treated with irradiation, mastectomy, and chemotherapy. In 29 patients, treatment consisted of preoperative once daily (16 patients) or twice daily (13 patients) irradiation with concurrent chemotherapy. In 27 (93%) of these 29 patients, this treatment was followed by mastectomy and additional chemotherapy. In 25 (86%) of these patients, major clinical response was attained, but an examination of the pathology of the operative specimen revealed complete tumor absence in only two patients (7%). The remaining seven patients underwent immediate mastectomy followed by once daily irradiation and chemotherapy. With a median follow-up of 30.4 months in all patients (59.2 months in surviving patients), the 5-year probability of relapse-free survival was 24% and of overall survival, 34%. Overall, the probability at 5 years of initial isolated local-regional tumor recurrence was 19%; in patients treated with once daily irradiation, the 5-year probability was 28%, whereas the probability was 8% with twice daily (accelerated) fractionated irradiation. Chemotherapy dose intensity did not appear to be adversely affected by the use of irradiation. The treatment approach described herein provides results comparable with those in other contemporary American series.

AB - Between January 1983 and April 1987, 36 consecutive patients with nonmetastatic clinical (30 patients) or occult (6 patients) inflammatory breast cancer were treated with irradiation, mastectomy, and chemotherapy. In 29 patients, treatment consisted of preoperative once daily (16 patients) or twice daily (13 patients) irradiation with concurrent chemotherapy. In 27 (93%) of these 29 patients, this treatment was followed by mastectomy and additional chemotherapy. In 25 (86%) of these patients, major clinical response was attained, but an examination of the pathology of the operative specimen revealed complete tumor absence in only two patients (7%). The remaining seven patients underwent immediate mastectomy followed by once daily irradiation and chemotherapy. With a median follow-up of 30.4 months in all patients (59.2 months in surviving patients), the 5-year probability of relapse-free survival was 24% and of overall survival, 34%. Overall, the probability at 5 years of initial isolated local-regional tumor recurrence was 19%; in patients treated with once daily irradiation, the 5-year probability was 28%, whereas the probability was 8% with twice daily (accelerated) fractionated irradiation. Chemotherapy dose intensity did not appear to be adversely affected by the use of irradiation. The treatment approach described herein provides results comparable with those in other contemporary American series.

UR - http://www.scopus.com/inward/record.url?scp=0026668504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026668504&partnerID=8YFLogxK

M3 - Article

C2 - 1524037

AN - SCOPUS:0026668504

VL - 15

SP - 376

EP - 387

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 5

ER -